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Abstract
Background: The use of alcohol and drugs may affect workplace safety and productivity. Little is known about the 
magnitude of this problem in Norway.
Methods: Employee recruitment methods with or without individual follow-up were compared. The employees filled 
in a questionnaire and provided a sample of oral fluid. Samples were analysed for alcohol, ethyl glucuronide (EtG; a 
biological marker of recent large alcohol intake), psychoactive medicinal drugs and illegal drugs.
Results: Participation rates with and without individual follow-up were 96% and 68%, respectively. Alcohol was 
negative (≤0.1 mg/ml) in all samples, but 21.0% reported the intake of alcohol during the last 24 h. EtG was positive 
(>2.2 ng/ml) in 2.1% of the samples. In-efficiency or hangover at work during the past year was reported by 24.3%, 
while 6.2% had been absent from work due to the use of alcohol. The combination of self-report and analytical testing 
indicated that medicinal or illegal drugs had been used during the last 48 h by 5.1% and 1.7% of the participants, 
respectively; while only 4.2% and 0.4% admitted the use in the questionnaire.
Conclusions: Self-reported data suggest that hangover after drinking alcohol appears to be the largest substance 
abuse problem at Norwegian workplaces, resulting in absence and inefficiency at work. Analysis of oral fluid revealed 
that the use of illegal drugs was more common than drinking alcohol before working or at the workplace. The analysis 
of oral fluid may be a valuable tool in obtaining additional information on alcohol and drug use compared to using 
questionnaires alone.
Background
Alcohol use may affect workplace safety and productivity
primarily in three ways: impairment due to the presence
of alcohol in the blood, residual after-effects after large
alcohol intake (in this report called "hang-over"), which
also may result in short-term sick leave, and long-term
sick leave due to chronic illnesses caused by alcohol abuse
[1].
The use of psychoactive drugs may also affect safety
and productivity. Approximately 20% of workers in Nor-
way are using prescribed medicinal drugs with abuse
potential, primarily sleeping agents, tranquillizers, and
opioid analgesics [2]. The use of illegal drugs is less com-
mon in Norway than in the USA and some countries in
southern Europe. In a Norwegian study published in
2001, only 2.7% of employees reported having used illegal
drugs during the previous 12 months [3], while in a study
performed in 2004, 2.2% of the general population
reported the use of cannabis during last month according
to the EMCDDA report for 2009 [4]. In comparison,
about 7% of the general population in Spain and Italy
reported the use of cannabis during last month [4], and
8.0% of American full-time workers and 10.2% of part-
time workers reported the use of illegal drugs during last
month according to the US national survey for 2008 [5].
Workplace drug testing (WDT) programmes were initi-
ated in the USA in the 1980s to reduce alcohol and drug
related accidents on the workplace [6]. Some companies
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experienced marked reduction in accidents after imple-
menting WDT programmes [7]. Studies on productivity
found that subjects testing positive for drugs used more
sick leave, and had higher risks for being fired, and had
higher turnover [8,9]. It was also claimed that WDT pro-
grammes would create drug-free workplaces which
would improve job satisfaction [10]. However, other stud-
ies were not able to confirm the findings mentioned
above. Today an important purpose of WDT pro-
grammes is to get substance abusing employees into
treatment, provide the opportunity to get help, and to get
the individuals back on the job [11].
WDT programmes are used for pre-employment test-
ing (e.g., requiring urine samples from job applicants) and
thus rejecting applicants being positive for illegal drugs,
but also for post-employment surveillance (e.g., requiring
urine samples from existing employees on a random,
comprehensive, or suspicion basis) and for follow-up
testing. The use of WDT is increasing in Europe, but is
n o t  a s  w i d e s p r e a d  a s  i n  t h e  U S A.  I n  E u r o p e  W D T  i s
mainly done in the transport, petrochemical, shipping,
automobile, pharmaceutical and computer industry, and
for call centres [12]. In Norway few companies have
implemented this type of programme.
Normally, urine samples are used for WDT. The sam-
ples are most commonly tested for amphetamines, can-
nabinoids, cocaine, opiates and sometimes
benzodiazepines and alcohol [12-14]. The finding of a
drug or drug metabolite in urine will not indicate drug
impairment at the time of sampling; it merely indicates
that the drug has been used within a time period of sev-
eral days or more prior to sampling, including use that
does not directly affect working safety or productivity.
Blood samples could be used to reveal possible alcohol
and drug influence at the time of sampling. Furthermore,
blood samples could also be used to look for biological
markers of high alcohol consumption and might there-
fore give more information about the alcohol consump-
tion during the last months [15,16]. Blood samples are
rarely used in WDT programmes because taking a blood
sample may be considered as a stronger invasion of pri-
vacy than taking a urine sample. Oral fluid may be used to
detect and monitor recent use of alcohol (i.e. during the
last 12 hours) and drugs (during the last 1-2 days), and
the use of oral fluid testing in WDT has been increasing
during the last years [17-20]. Oral fluid is an easily avail-
able medium that can be collected with non-invasive
methods without the intrusion of privacy and with little
chance of adulteration (unlike urine). Oral fluid has about
the same detection time window as blood regarding alco-
hol and drugs, and can to some extent be a substitute for
blood samples; oral fluid is probably the only other easily
a v a i l a b l e  b o d y  fl u i d  t h a t  m i g h t  p a r a l l e l  b l o o d  i n  s o m e
regards and may be related to behavioural performance
[21]. The presence of drugs or drug metabolites in oral
fluid indicate very recent drug intake [22], and reflects
better than urine whether the subject may be impaired by
drugs or alcohol at time of sampling [21].
Ethyl glucuronide (EtG) is a metabolite of alcohol that
can be used as biological markers of recent alcohol intake
[23-27]. EtG is usually measured in samples of urine or
blood, but can also be detected in oral fluid [28]. High
concentrations of EtG in oral fluid might reflect very
recent intake of large amounts of alcohol even when no
alcohol can be detected in the blood. However, the con-
centration of EtG in oral fluid, blood or urine does not
reflect the alcohol consumption over a longer period of
time and can therefore not be used to uncover excessive
alcohol consumption or alcoholism. The kinetics of EtG
in oral fluid compared to blood and urine has recently
been published [29].
The aims of this pilot project were: to compare self-
reported alcohol and drug use with results from analysis
of oral fluid, to obtain information about the use of alco-
hol and drugs in the Norwegian workplace, and to exam-
ine some of the consequences that alcohol and drug use
may have for sick leave, in-efficiency and hang-over at
work. An additional aim was to compare two procedures
for recruiting participants: one procedure with close con-
tact between study personnel and employees and another
procedure without.
Methods
The procedures for recruitment of companies and
employees was agreed upon in a meeting with represen-
tatives from The Norwegian Business and Industry Secu-
rity Council, The Workplace Advisory Centre for Issues
Related to Alcohol, Drugs and Addictive Gambling in the
Workplace, and the Confederation of Norwegian Enter-
prises. The study was approved by the Regional Commit-
tee for Medical and Health Research Ethics.
Subjects
Ten companies, research institutes and public adminis-
tration bodies (hereafter called the "companies") were
invited to participate in the project. In addition, adver-
tisements were published in newsletters, newspapers and
on websites, resulting in responses from two companies.
In total, only four companies decided to participate. In
addition, we collaborated with the Norwegian Transport
Directorate at one checking station for heavy vehicles to
include truck drivers.
The employees were recruited at the participating com-
panies by first selecting one day for each company, then
contacting all employees who either were present in the
building or who passed the main entrance door during
defined time periods. Employees were recruited withinGjerde et al. Journal of Occupational Medicine and Toxicology 2010, 5:13
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the first three hours after starting their work in the morn-
ing.
Occupational drivers were recruited at a checking sta-
tion by first selecting two days, then contacting as many
drivers as possible during two 2-hour periods within the
timeframes of the scheduled heavy vehicle checks deter-
mined by the Norwegian Transport Directorate, covering
both day and night.
Written and verbal information about the project was
given, and participation was voluntary and anonymous.
Two approaches for recruiting participants were used,
but only one method within each company.
Recruitment procedure "A"
In some companies and for all occupational drivers, each
employee was approached individually by one project
assistant and asked to participate. An explanation about
the project was given, and each person had the opportu-
nity to ask questions. Those who agreed to participate
completed a written questionnaire and provided an oral
fluid specimen. The filled-in questionnaire and the sam-
ple of oral fluid were placed in a closed envelope and were
collected by the project assistant either immediately of
within short time of up to one hour.
Recruitment procedure "B"
For other companies, an envelope containing the ques-
tionnaire and sampling kit for oral fluid, including
instructions for use, were given to random employees
when entering the company facilities in the morning. The
employees were asked to deliver the questionnaire and
the oral fluid sample in closed envelopes at specified sites
be f or e  noon.  T hey we r e giv en t he  pho ne n um be r o f  a
project assistant so that they could ask questions, if nec-
essary.
Sampling of oral fluid
Oral fluid was sampled using the Statsure Saliva Sam-
pler™ (Statsure Diagnostic Systems, Framingham MA,
USA), which had an indicator that turned blue when
about 1.0 ml oral fluid had been collected. This device did
not contain any saliva-stimulating agents. It was chosen
because initial testing showed that samples collecting
with this device were better suitable for the analysis of
EtG than some other devices. For recruitment procedure
"A", samples were chilled (about 2-8°C) for up to 10 hours,
and thereafter kept frozen until the analyses were per-
formed. For collection procedure "B", samples were kept
at room temperature (about 22-25°C) for up to 5 hours
before frozen.
Analytical methods
Alcohol was determined by an enzymatic method [30].
The method was initially developed for the analysis of
alcohol in blood and urine. Before we used it in this study,
the method was validated for the analysis of alcohol in
oral fluid. EtG and drugs were analysed by liquid chroma-
tography - tandem mass spectroscopy [28,31]. The com-
pounds analysed and the cut-off concentrations (in the
mixture of oral fluid and buffer) are presented in Table 1.
The cut-off concentrations were lower than those pro-
posed by SAMHSA [32] in the USA because we wanted
to detect all recent use of medicinal and illegal drugs to
compare with self-reported drug use. The following
drugs were defined as illegal: amphetamine, metham-
phetamine, MDA, MDEA, MDMA (ecstacy), cocaine,
THC, and 6-monoacetylmorphine.
Statistical methods
Pearson's Chi-Square two-sided test for categorical vari-
ables was used for statistical evaluation of results in rela-
tion to age group by using SPSS 14.0 statistical software
(SPSS Inc., Chicago, IL, USA).
Results
A total of 526 employees participated in the study, repre-
senting research and development (n = 82), manufactur-
ing and warehouse (n = 107), transportation (n = 126)
and public administration (n = 211). Of these, 181 were
women and 281 were men, while 64 subjects did not
report the gender in the questionnaire. All age groups
were represented. Two individuals did not provide sam-
ples of oral fluid, while seven did not fill in the question-
naire.
Participation rates
The total participation rate was 82%. For the employees
who were followed-up individually by a project assistant
(recruitment procedure "A"), the participation rate was
96%, while when the employee was asked to deliver the
questionnaire and sample in boxes at specified sites
(recruitment procedure "B"), the participation rate was
68%.
Age and gender
The distributions of age and gender were different for the
companies studied. As a result of the fact that only one
recruitment procedure was used in each company, and
that few companies participated, the distribution of age
and gender were different for the participants recruited
with the two procedures. For recruitment procedure "A",
16.5% were females and 20.1% were below 30 years of age;
while for recruitment procedure "B", 61.1% were females
and 8.5% were below 30 years of age. Therefore, we have
not sufficient data to perform a good comparison of men
and women, different age groups, or different recruit-
ment procedures.
Results of questionnaire and analysis of oral fluid
The principal results of the questionnaire and analysis of
oral fluid are presented in Table 2. Drug concentrations inGjerde et al. Journal of Occupational Medicine and Toxicology 2010, 5:13
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oral fluid and possible explanations are presented in
Table 3 for all cases where drugs were found.
When using recruitment procedure "A", which had a
participation rate of 96%, 0.7% reported the use of illegal
drugs in the questionnaire, whereas such drugs were
found in 2.2% of the oral fluid samples (results not
shown). In total, 3.0% either reported use of illegal drugs
or were found to be positive for illegal drugs when
analysing oral fluid. Of those with procedure "B", none
reported illegal drug use, and no oral fluid sample was
positive for illegal drugs.
As the number of men recruited with procedure "A" was
fairly high, a comparison of males below and above 35
years of age was performed, results are presented in Table
4.
Discussion
The primary aims of this pilot project were to compare
self-reported use of alcohol and drugs with analytical
results for oral fluid, to demonstrate the usefulness of EtG
as a marker of large alcohol intake before a working ses-
sion, to study the participation rate when using two pro-
Table 1: Substances analysed and cut-off limits
Substance Description Cut-off
ng/ml
Alcohol (ethanol) Alcoholic beverages 0.1 mg/ml
Ethyl glucuronide Metabolite of ethanol 2.2
Alprazolam Benzodiazepine; anxiolytic 0.23
Amphetamine Stimulant. Mostly used illegally in Norway 12.2
Benzoylecgonine Degradation product and metabolite of cocaine 3.6
Carisoprodol Muscle relaxant 13.0
Clonazepam Benzodiazepine; anticonvulsant, anxiolytic 0.24
Cocaine Stimulant; illegal in Norway 0.91
Codeine Opiate analgesic, antitussive, antidiarrheal properties 3.7
Diazepam Benzodiazepine; anxiolytic, anticonvulsant, sedative, skeletal muscle 
relaxant
0.18
Flunitrazepam Benzodiazepine; hypnotic 0.16
Lorazepam Benzodiazepine; sedative, hypnotic, muscle relaxant, anxiolytic, 
anticonvulsant
0.48
Methadone Opiate analgesic. Treatment of heroin addiction 3.9
Methamphetamine Stimulant. Illegal in Norway 7.5
Meprobamate Metabolite of carisoprodol 10.9
Morphine Opiate analgesic. Also metabolite of codeine and heroin 3.6
Nitrazepam Benzodiazepine; hypnotic 0.21
Nordiazepam Psychoactive metabolite of diazepam 0.34
Oxazepam Benzodiazepine; anxiolytic, anticonvulsant, sedative skeletal muscle 
relaxant
2.4
Tetrahydrocannabinol Cannabis, hashish, marijuana (THC) 0.31
Zolpidem Short-acting non-benzodiazepine hypnotic 0.08
Zopiclone Short-acting non-benzodiazepine hypnotic 0.49
3,4-methylenedioxy amphetamine Illegal psychedelic hallucinogenic drug (MDA) 9.0
3,4-methylenedioxy-N-ethylamphetamine Illegal psychedelic hallucinogenic drug (MDEA) 10.3
3,4-methylenedioxy-N-methylamphetamine Illegal psychedelic hallucinogenic drug (MDMA) 1.9
6-monoacetylmorphine Degradation product and metabolite of heroin, only illegal use in 
Norway
0.41
7-aminoclonazepam Degradation product and metabolite of clonazepam 0.36
7-aminoflunitrazepam Degradation product and metabolite of flunitrazepam 0.07
7-aminonitrazepam Degradation product and metabolite of nitrazepam 0.31Gjerde et al. Journal of Occupational Medicine and Toxicology 2010, 5:13
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cedures for the collection of questionnaires and samples
of oral fluid, and to collect some preliminary data on
alcohol and drug use in the workplace in Norway.
Only a few additional cases of alcohol use, as indicated
by the presence of EtG, were detected when analysing
oral fluid in addition to using a questionnaire. However,
the detection of EtG indicates an alcohol consumption of
more than six drinks the night before [29], and a large
proportion of the EtG-positive subjects did not report an
alcohol consumption of that magnitude. Thus, the inci-
dence of large alcohol intake was under-reported in the
questionnaires. This agrees with the finding in a previous
study, where the self-reported alcohol consumption was
found to be significantly lower than actual alcohol con-
sumption [33].
The analysis of oral fluid revealed some additional drug
users compared to self-reported use. The use of psycho-
active medicinal drugs was reported by 4.2%, but addi-
Table 2: Positive responses from questionnaire and analysis of oral fluid
Questionnaire (n = 519) n%
Consumed alcohol within the last 24 h 109 21.0
Consumed 4 or more drinks within 24 h 10 1.9
Absent from work due to drinking alcohol during last 12 months 32 6.2
In-efficiency or hangover at work due to alcohol during last 12 months 126 24.3
Consumed 6 drinks or more in one session at least once a month 105 20.2
Deficient memory after drinking session at least once last 12 months 101 19.5
Deficient memory after drinking session at least once a month 6 1.2
Used medicinal drugs within 48 h 22 4.2
Absent from work because of using medicinal drugs during last 12 months 10 1.9
In-efficiency at work because of using medicinal drugs during last 12 months 17 3.3
Used illegal drugs within 48 h 20 . 4
Absent from work because of using illegal drugs during last 12 months 2 0.4
In-efficiency at work because of using illegal drugs during last 12 months 3 0.6
Analysis of oral fluid (n = 524) n %
Alcohol 00 . 0
Ethyl glucuronide 11 2.1
Medicinal drugs 14 2.7
Zopiclone 71 . 3
Zolpidem 20 . 4
Diazepam 40 . 8
Codeine 10 . 2
Illegal drugs 71 . 3
THC 51 . 0
Methamphetamine 20 . 4
Use of alcohol or drugs as revealed by oral fluid analysis and/or self-reporting (n = 526) n %
Alcohol within last 24 h1 114 21.7
Consumed 4 or more drinks during last 24 h1 18 3.4
Used medicinal drugs within last 48 h2 27 5.1
Used illegal drugs within last 48 h2 91 . 7
1Self-reported alcohol intake or EtG detected in oral fluid.
2Self-reported use or drug detected in oral fluid.Gjerde et al. Journal of Occupational Medicine and Toxicology 2010, 5:13
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tional 0.9% was found by analysing oral fluid. The use of
illegal drugs was reported by only 0.4%, and additional
1.3% was found by analysing oral fluid. Thus, users of ille-
gal drugs were much more reluctant to admitting drug
use than users of alcohol and medicinal drugs. Similar
results have been found in other studies [34,35]. Since
about 20% of the invited employees refused to participate,
the real fraction of employees that had used illegal drugs
during the last 48 hours may probably be higher.
The participation rate was very high if each employee
was met individually before and after the questionnaire
was filled in and the sample of oral fluid was collected. If
the employees were asked to return the questionnaire and
sample in a container within a couple of hours for later
pick-up by the project team, the participation rate was
significantly lower.
The use of illegal drugs was most commonly detected
when the participation rate was high. This may suggest
that a larger number of employees who suspected that a
sample of oral fluid would reveal the use of illegal drugs
refused to participate when not being followed up indi-
vidually by a project assistant. However, differences in
Table 3: Cases where drug was detected in oral fluid
Subject Drug findings in oral fluid Possible explanation
Female, <25 y Zopiclone 3 ng/ml Sleeping tablet the night before
Female, 35-39 y Zopiclone 8 ng/ml Sleeping tablet the night before
Female, 45-49 y Zopiclone 23 ng/ml Sleeping tablet the night before
Female, 50-54 y Zopiclone 13 ng/ml Sleeping tablet the night before
Female, 55-59 y Zopiclone 13 ng/ml Sleeping tablet the night before
Male, 60-64 y Zopiclone 3 ng/ml Sleeping tablet the night before
Male, 35-39 y Zopiclone 47 ng/ml Sleeping tablet the night before
Male, <25 y Zolpidem 0.4 ng/ml Sleeping tablet the night before
Male, 55-59 y Zolpidem 1.2 ng/ml Sleeping tablet the night before
Male, 50-54 y Diazepam 1.0 ng/ml, nordiazepam 2.4 ng/ml Normal therapeutic use
Male, 55-59 y Diazepam 0.4 ng/ml Normal therapeutic use
Male, 55-59 y Codeine 137 ng/ml Normal therapeutic use
Male, <25 y THC 6 ng/ml Cannabis use >6 h earlier
Male, 25-29 y THC 1102 ng/ml Recent cannabis use
Male, 30-34 y THC 6 ng/ml Cannabis use >6 h earlier
Male, 30-34 y THC 17 ng/ml Recent cannabis use
Male, 35-39 y THC 294 ng/ml Recent cannabis use
Male, 35-39 y Methamphetamine 1067 ng/ml, amphetamine 188 ng/ml, 
diazepam 1.8 ng/ml
Recent intake of moderate doses, or large doses 1-2 days 
ago
Male, 40-44 y Methamphetamine 14700 ng/ml, amphetamine 1052 ng/ml, 
diazepam 275 ng/ml
Recent intake of large doses
Table 4: Drug and alcohol use and consequences of alcohol use among male employees followed up individually.
Age <35 years
n = 66
%
Age ≥35 years
n = 151
%
p-value1
Consumed 6 drinks or more in one occasion at least once a month 36.9 18.5 0.005
Absent from work due to consumption of alcohol during last 12 months 13.4 3.3 0.005
In-efficiency or hangover at work due to alcohol during last 12 months 29.9 10.7 0.001
Deficient memory after drinking session at least once last year 29.2 16.0 0.027
Use of psychoactive medicinal drugs during the last 48 hours2 1.5 5.3 0.199
Use of illegal drugs during the last 48 hours2 6.1 2.0 0.118
1Chi square test for differences between age groups. 2Self-reported use or drug detected in oral fluid.Gjerde et al. Journal of Occupational Medicine and Toxicology 2010, 5:13
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gender and age distributions between companies using
the two recruitment procedures may be contributing to
the observed difference.
In our study of male workers using procedure "A", both
the incidences of binge drinking (more than 6 drinks in
one occasion), absence from work, hangover and defi-
cient memory were significantly higher among men
below 35 years of age compared to older men. Similar
result were found in a previous study [2]. The use of ille-
g a l  d r u g s  s e e m e d  a l s o  t o  b e  m o r e  p r e v a l e n t  a m o n g
younger men, although not statistically significant; how-
ever, in a previous survey among random drivers, the
highest prevalence of illegal drugs was also seen among
young male drivers [36]. The use of psychoactive medici-
nal drugs seemed to be more prevalent among men at an
age of 35 or higher. Similar results were found among
drivers [36]. Data from the Norwegian Prescription Data-
base [37] confirms that the use of psychoactive medicinal
drugs is more common among older men.
There is a large variation in drug concentrations ratios
between oral fluid and blood, so blood drug concentra-
tions cannot be accurately estimated by using concentra-
tions in oral fluid [38]. Drug concentrations in oral fluid
can neither be used to assess psychomotor impairment
nor assess whether decision-making is affected. However,
the drug findings may be used to suggest whether or not a
person has used a normal therapeutic dose of a medicinal
drug, or whether or not the use of an illegal drug hap-
pened shortly before sampling. The concentrations of
medicinal drugs found in our study suggested that nor-
mal therapeutic doses of medicinal drugs had been used,
except in one case where also methamphetamine had
been taken.
A combination of methamphetamine and diazepam
was found in two samples. In those cases, amphetamine
was also detected as a metabolite of methamphetamine.
The combination of methamphetamine and sedatives
may indicate chronic addictive methamphetamine use.
The detection time frame for methamphetamine in oral
fluid has been reported to be about 24 hours [39], but
might be longer after intake of large doses. In one case
the concentrations of both methamphetamine and diaze-
pam were very high, indicating very recent intake of large
doses. In the second case, the intake may have happened
1-2 days ago, or a smaller dose might have been taken
recently. The abuse of amphetamines should be a serious
concern for their employers.
The detection time frame for THC in oral fluid is about
34 hours [40]. We found both very high and fairly low
concentrations of THC in our study. In a study performed
by Kauert and co-workers, THC concentrations of 18 ±
12 ng/ml were observed 6 hours after smoking cannabis
[41]. Similar results were observed in another study [42].
Based on these results, it is likely that three of the five
subjects with positive THC findings in our study had
smoked cannabis within 6 hours before sampling of oral
fluid.
It seems likely that three to five of the seven workers
who had used illegal drugs had probably reduced working
performance at the time of sampling of oral fluid.
EtG was found in samples from 11 subjects. Knowing
that an alcohol intake corresponding to six drinks or
more is needed in order to give detectable concentration
of EtG in oral fluid about 12 hours after start of drinking
[29], we may assume that a proportion of those subjects
experienced hangover at work at the time of oral fluid
sampling. Hangover after alcohol use may be a more sig-
nificant reason for reduced performance among Norwe-
gian employees than alcohol impairment at work. This is
also in compliance with the self-reported inefficiency or
hangover at work using the questionnaire.
Conclusions
Our findings suggest that analysis of oral fluid may be a
valuable tool in obtaining supplementary information
when performing studies on the use of alcohol and drugs
with questionnaires, particularly regarding the use of ille-
gal drugs, which was very much under-reported. Our
findings also suggest that the use of drugs may be more
common than drinking alcohol prior to working or at the
workplace. Self-reported data suggest that hangover after
alcohol use may be a more significant problem at the
workplace than impairment by alcohol or drugs at work.
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